EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access

Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction

John Steytler, Charles Craig, Elna van der Ryst, Ben Van Baelen, Jeremy Nuttall, Neliëtte van Niekerk, John Mellors, Urvi Parikh, Carole Wallis, Ring Study and the DREAM Trial Study Teams

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac875 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von John Steytler und 9 weiteren Autor:innen. Beteiligte Einrichtung: International Partnership for Microbicides South Africa NPC, Johannesburg, South Africa. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Seropositivity, Contraceptive Devices, Female. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Danish Ministry of Foreign Affairs, Flanders Ministry of Foreign Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Ring Study demonstrated 35.1% human immunodeficiency virus type 1 (HIV-1) infection risk reduction among participants who used the Dapivirine vaginal ring-004 (DVR), whereas the Dapivirine Ring Extended Access and Monitoring (DREAM) trial, approximated a 62% risk reduction. The observed non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance-associated mutations (RAMs) and effects on viral susceptibility are described here.

Methods

Population-based genotyping on plasma samples collected longitudinally, and next-generation sequencing (NGS) and phenotypic susceptibility testing were done on plasma collected at seroconversion. Retrospective HIV-1 RNA testing was used to more accurately establish the time of infection.

Results

In the Ring Study, NNRTI RAMs were not observed in most viruses at seroconversion (population-based genotyping: DVR: 71 of 84, 84.5%; placebo: 50 of 58, 86.2%). However, more E138A was found in the DVR group (E138A DVR: 9 of 84, 10.7%; placebo: 2 of 58, 3.4%; P = .2, Fisher exact test). NGS detected 1 additional mutation in each group (DVR: G190A; placebo: G190A and G190E). Marginal dapivirine susceptibility reduction was found with NNRTI RAMs at seroconversion (geometric mean fold-change, range: DVR, 3.1, 1.3–5.1; placebo, 5.8, 0.9–120). NNRTI RAMs were not emergent between first detectable HIV-1 RNA and seroconversion when these visits differed (paired samples, mean ring use: DVR, n = 52, 35 days; placebo, n = 26, 31 days). After stopping DVR, 2 of 63 viruses had emergent G190G/A or K103K/N with V106V/M at final study visit. Resistance profiles from the DREAM trial were consistent with the Ring Study.

Conclusions

DVR showed little potential for selection of NNRTI-resistant variants. Clinical Trials Registration NCT01539226 and NCT02862171.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHIV SeropositivityContraceptive Devices, FemaleAnti-HIV AgentsFemaleHumansRetrospective StudiesReverse Transcriptase InhibitorsRNAPyrimidines

Stichwörter der Autor:innen

Dapivirine vaginal ring-004HIV-1antiretroviral drug susceptibilitypreexposure prophylaxis

Substanzen

Reverse Transcriptase InhibitorsRNAAnti-HIV AgentsDapivirinePyrimidines

Autor:innen und Institutionen

  • International Partnership for Microbicides South Africa NPC, Johannesburg, South Africa.
  • Research Virology Consulting Ltd, Cambridgeshire, United Kingdom.
  • Independent Consultant, Kent, United Kingdom.
  • BVB Clin Consult BVBA, Herent, Belgium.
  • International Partnership for Microbicides, Silver Spring, Maryland, USA.
  • Microbicide Trials Network Virology Core Laboratory, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Förderung

  • NCI NIH HHS
  • Danish Ministry of Foreign Affairs
  • Flanders Ministry of Foreign Affairs
  • Irish Aid
  • Ministry of Foreign Affairs of the Netherlands
  • Norwegian Agency for Development Cooperation
  • UK Government's Foreign, Commonwealth & Development Office
  • US Agency for International Development

Zitieren

APA

Steytler, J., Craig, C., van der Ryst, E., Van Baelen, B., Nuttall, J., van Niekerk, N., Mellors, J., Parikh, U., Wallis, C., & Ring Study and the DREAM Trial Study Teams (2023). Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac875

Vancouver

Steytler J, Craig C, van der Ryst E, Van Baelen B, Nuttall J, van Niekerk N, et al. Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac875

BibTeX
@article{Steytler2023,
  author = {Steytler, John and Craig, Charles and van der Ryst, Elna and Van Baelen, Ben and Nuttall, Jeremy and van Niekerk, Neliëtte and Mellors, John and Parikh, Urvi and Wallis, Carole and Ring Study and the DREAM Trial Study Teams, Ring Study and the DREAM Trial Study Teams},
  title = {Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac875}
}
Kostenlos starten →